LY-411575

LY-411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with an IC50 of 0.39 nM.

Product Specifications

CAS Number

[209984-57-6]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Apoptosis; Notch; Organoid; γ-secretase

Type

Reference compound

Related Pathways

Apoptosis; Neuronal Signaling; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ly-411575.html

Purity

98.68

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C1[C@@H](NC([C@@H](NC([C@H](C2=CC(F)=CC(F)=C2)O)=O)C)=O)C3=CC=CC=C3C(C=CC=C4)=C4N1C

Molecular Formula

C26H23F2N3O4

Molecular Weight

479.48

Precautions

H315, H319, H320

References & Citations

[4]Otoguro T, et al. Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity. Microbiol Immunol. 2016 Nov;60 (11) :740-753|[5]Zhang J, et al. Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition. Histochem Cell Biol. 2017 Mar;147 (3) :367-375.|[1]Wong GT, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004 Mar 26;279 (13) :12876-82.|[2]Curry CL, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene. 2005 Sep 22;24 (42) :6333-44.|[3]Hyde LA, et al. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[ (2S) -2- (3,5-difluorophenyl) -2-hydroxyethanoyl]-N1-[ (7S) -5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b, d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther. 2006 Dec;319 (3) :1133-43.